Cargando…
Next generation Fc scaffold for multispecific antibodies
Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hind...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633962/ https://www.ncbi.nlm.nih.gov/pubmed/34877503 http://dx.doi.org/10.1016/j.isci.2021.103447 |
_version_ | 1784608037127847936 |
---|---|
author | Estes, Bram Sudom, Athena Gong, Danyang Whittington, Douglas A. Li, Vivian Mohr, Christopher Li, Danqing Riley, Timothy P. Shi, Stone D.-H. Zhang, Jun Garces, Fernando Wang, Zhulun |
author_facet | Estes, Bram Sudom, Athena Gong, Danyang Whittington, Douglas A. Li, Vivian Mohr, Christopher Li, Danqing Riley, Timothy P. Shi, Stone D.-H. Zhang, Jun Garces, Fernando Wang, Zhulun |
author_sort | Estes, Bram |
collection | PubMed |
description | Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3′ interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies. |
format | Online Article Text |
id | pubmed-8633962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86339622021-12-06 Next generation Fc scaffold for multispecific antibodies Estes, Bram Sudom, Athena Gong, Danyang Whittington, Douglas A. Li, Vivian Mohr, Christopher Li, Danqing Riley, Timothy P. Shi, Stone D.-H. Zhang, Jun Garces, Fernando Wang, Zhulun iScience Article Bispecific antibodies (Bispecifics) demonstrate exceptional clinical potential to address some of the most complex diseases. However, Bispecific production in a single cell often requires the correct pairing of multiple polypeptide chains for desired assembly. This is a considerable hurdle that hinders the development of many immunoglobulin G (IgG)-like bispecific formats. Our approach focuses on the rational engineering of charged residues to facilitate the chain pairing of distinct heavy chains (HC). Here, we deploy structure-guided protein design to engineer charge pair mutations (CPMs) placed in the CH3-CH3′ interface of the fragment crystallizable (Fc) region of an antibody (Ab) to correctly steer heavy chain pairing. When used in combination with our stable effector functionless 2 (SEFL2.2) technology, we observed high pairing efficiency without significant losses in expression yields. Furthermore, we investigate the relationship between CPMs and the sequence diversity in the parental antibodies, proposing a rational strategy to deploy these engineering technologies. Elsevier 2021-11-15 /pmc/articles/PMC8633962/ /pubmed/34877503 http://dx.doi.org/10.1016/j.isci.2021.103447 Text en © 2021 The Authors. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Estes, Bram Sudom, Athena Gong, Danyang Whittington, Douglas A. Li, Vivian Mohr, Christopher Li, Danqing Riley, Timothy P. Shi, Stone D.-H. Zhang, Jun Garces, Fernando Wang, Zhulun Next generation Fc scaffold for multispecific antibodies |
title | Next generation Fc scaffold for multispecific antibodies |
title_full | Next generation Fc scaffold for multispecific antibodies |
title_fullStr | Next generation Fc scaffold for multispecific antibodies |
title_full_unstemmed | Next generation Fc scaffold for multispecific antibodies |
title_short | Next generation Fc scaffold for multispecific antibodies |
title_sort | next generation fc scaffold for multispecific antibodies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633962/ https://www.ncbi.nlm.nih.gov/pubmed/34877503 http://dx.doi.org/10.1016/j.isci.2021.103447 |
work_keys_str_mv | AT estesbram nextgenerationfcscaffoldformultispecificantibodies AT sudomathena nextgenerationfcscaffoldformultispecificantibodies AT gongdanyang nextgenerationfcscaffoldformultispecificantibodies AT whittingtondouglasa nextgenerationfcscaffoldformultispecificantibodies AT livivian nextgenerationfcscaffoldformultispecificantibodies AT mohrchristopher nextgenerationfcscaffoldformultispecificantibodies AT lidanqing nextgenerationfcscaffoldformultispecificantibodies AT rileytimothyp nextgenerationfcscaffoldformultispecificantibodies AT shistonedh nextgenerationfcscaffoldformultispecificantibodies AT zhangjun nextgenerationfcscaffoldformultispecificantibodies AT garcesfernando nextgenerationfcscaffoldformultispecificantibodies AT wangzhulun nextgenerationfcscaffoldformultispecificantibodies |